Mortality in people taking selegiline: Observational study

British Medical Journal

Volumn 317, Issue 7153, 1998, Pages 252-254

  Thorogood, Margaret ^a   Armstrong, Ben ^a   Nichols, Tom ^a   Hollowell, Jen ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b OFFICE FOR NATIONAL STATISTICS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; NEUROLEPTIC AGENT; SELEGILINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DATA BASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PARKINSON DISEASE; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0032566217     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.317.7153.252     Document Type: Article

References (6)

1. Parkinson's Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. BMJ 1993;307:469-72.
2. Lees AJ. on behalf of the Parkinson's Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995;311:1602-7.
3. Hollowell J. The General Practice Research Database: quality of morbidity data. Population Trends 1997;87.
4. Bennett DA, Beckett LA, Murray AM, Shannon KM, Goetz CG, Pilgrim DM, et al. Prevalence of parkinsonian signs and associated mortality in a community populaton of older people. N Engl J Med 1996;331:71-6.
5. McCormick A, Fleming D, Chartlon J, eds. Morbidity statistics from general practice: fourth national study 1991 1992. London: HMSO, 1995. (Series MB5 No 3.)
6. Office of Population Censuses and Surveys. Longitudinal study: mortality and social organisation. London: HMSO, 1990.